Goldman Sachs’s Sigilon Therapeutics, Inc. Common Stock SGTX Stock Holding History

Goldman Sachs’s Portfolio SGTX Stock Details SGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-2,200	Closed	-$26.6K	–	6248
2023 Q1	$26.6K	Buy	2,200 +900	+69%	+$9.35K	﹤0.01%	5640
2022 Q4	$5.92K	Sell	1,300 -25	-2%	-$143	﹤0.01%	5802
2022 Q3	$9K	Buy	1,325 +15	+1%	+$137	﹤0.01%	6040
2022 Q2	$14K	Buy	1,310 +144	+12%	+$1.94K	﹤0.01%	6228
2022 Q1	$22K	Sell	1,166 -3,105	-73%	-$69.2K	﹤0.01%	6399
2021 Q4	$154K	Buy	4,271 +589	+16%	+$33.5K	﹤0.01%	6000
2021 Q3	$270K	Buy	3,682 +1,101	+43%	+$84.7K	﹤0.01%	5568
2021 Q2	$360K	Buy	2,581 +1,070	+71%	+$188K	﹤0.01%	5412
2021 Q1	$439K	Sell	1,511 -1,181	-44%	-$470K	﹤0.01%	5216
2020 Q4	$1.68M	Buy	+2,692	New	+$1.22M	﹤0.01%	3844

Other funds holding SGTX

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return

YCM

Yakira Capital Management Westport, Connecticut $342M AUM 26.97% 1-Year Est. Return

State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CSS LLC Chicago, Illinois $2.09B AUM 59.56% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs's SGTX Position: Q2 2023 in Review

Goldman Sachs sold out of Sigilon Therapeutics, Inc. Common Stock (SGTX) in Q2 2023, closing a stake of 2,200 shares — an estimated $26.6K sold.

Goldman Sachs first reported a position in SGTX in Q4 2020 and held it in 10 quarters. The position peaked at $1.68M in Q4 2020. 16 funds tracked by Wall St. Rank hold SGTX as of Q2 2023.

Goldman Sachs reported no remaining Sigilon Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Goldman Sachs sold 2,200 Sigilon Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $26.6K.
Goldman Sachs first reported a position in Sigilon Therapeutics, Inc. Common Stock in Q4 2020 and held it in 10 quarters.
Goldman Sachs's Sigilon Therapeutics, Inc. Common Stock position peaked at $1.68M in Q4 2020.
16 funds tracked by Wall St. Rank held Sigilon Therapeutics, Inc. Common Stock as of Q2 2023.

Based on Goldman Sachs's 13F filing for Q2 2023, filed 15 Aug 2023.